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Summary To understand genetic events which play a role in the development and/or progression of human
endometrial cancer, we studied allelotypes on all autosomal chromosomes, as well as chromosome X, with 42
microsatellite markers and 56 endometrial cancers. The most frequent loss of heterozygosity (LOH) was
observed on the long arm ofchromosome 10 (14 of 30, 47%), which was commonly detected in grade 1 cancer.
We constructed a detailed deletion map and defined two commonly deleted regions in 1Oq25-q26; one was the
8 cM region between DlOS209 and DIOS216, the other was the 12 cM region between DIOS217 and DIOS590.
Replication errors at two or more loci were observed in 24 of 56 tumours (43%), suggesting that disruption of
the DNA mismatch repair system also plays an important role in the course of endometrial carcinogenesis.
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Endometrial cancer is one of the most common female pelvic
malignant diseases in the world. Approximately 33 000 new
cases are diagnosed annually in the United States (Parkin et
al., 1988). The incidence in Japan is 4.01 cases per 100-000
females in 1989 (Fujimoto et al., 1993). Moreover, the rate of
endometrial cancer is increasing yearly and has doubled in
Japan in the last 10 years (Fujimoto et al., 1993). Although
recent advances in medical science have revealed molecular
mechanisms in some cancers, such as colorectal cancer
(Fearon and Vogelstein, 1990), only a limited amount of
information about the molecular mechanism in endometrial
carcinogenesis has been reported. In previous studies, p53
and ras appeared to be involved in the development of
endometrial cancer, but the incidence of alterations in these
two genes was not high; the reported mutation frequency of
p53 is 10-20% (Okamoto et al., 1991; Risinger et al., 1992)
and activation of K-ras is 10-30% (Enomoto et al., 1990,
1991; Ignar-Trowbridge et al., 1992). Microsatellite instabil-
ity, one of the major mechanisms in cancer susceptibility, has
been reported in about 20% of sporadic endometrial cancer
(Han et al., 1993; Risinger et al., 1993; Duggan et al., 1994;
Burks et al., 1994; Peiffer et al., 1995), and a mutation of
hMLHI was found in a sporadic case of endometrial cancer
(Fukushige et al., 1996). Thus, defects in DNA mismatch
repair genes have been implicated in some fraction of
endometrial cancers. However, it is not clear whether defects
in DNA mismatch repair genes result in genetic alteration in
oncogenes and/or tumour-suppressor genes that are asso-
ciated with endometrial carcinogenesis. Moreover, molecular
mechanisms, including genes, that play an important role in
endometrial carcinogenesis are still an open question. As the
first step in obtaining a better understanding of molecular
mechanisms ofendometrial carcinogenesis, we analysed allelic
losses to search for loci that may harbour putative tumour-
suppressor genes. Although several investigators have
reported frequent LOH on chromosome arms 3p, 10q, 17p
and 18q (Okamoto et al., 1991; Jones et al., 1994; Fujino et
al., 1994; Peiffer et al., 1995), investigations are not yet
complete. In the present study, we analysed allelotypes in 56
endometrial cancers using 42 microsatellite markers that
spanned all chromosome arms and identified frequent allelic
losses on chromosome arms 10q and 16q; 10q showed a
strikingly high incidence of deletion. For these reasons, we
constructed a detailed deletion map of the long arm of
chromosome 10 in endometrial cancers. Here, we report the
identification of two commonly deleted regions in chromo-
some arm 1Oq.
Materials and methods
Tissue samples and DNA extraction
Since contamination of normal cells in cancerous tissue
would mask allelic loss, which would lead to erroneous
interpretation of LOH studies, we examined 71 endometrial
cancer tissues histopathologically and selected 56 tumours in
which contamination by normal cells was less than 50% of
the total. All the surgically removed samples analysed in the
present study were obtained from Japanese patients in
Tohoku University Hospital and its related hospitals.
Tissues were fixed in formalin and embedded in paraffin.
DNAs were extracted according to methods described
previously (Goelz et al., 1985; Yanagisawa et al., 1991).
Histopathological diagnosis and clinical staging were
classified according to the criteria of the International
Federation of Gynecology and Obstetrics (1989) (see Table I).
Allelotype analysis
A total of 42 microsatellite markers on all autosomal
chromosomes, as well as chromosome X, were used for
allelotype analysis of endometrial carcinoma. Since our
samples were obtained from tissues fixed in formalin, it was
difficult to amplify 150 bp or more by polymerase chain
reaction (PCR). Therefore, we designed primers to amplify
about 100 bp according to the GenBank database. Details of
the microsatellite markers and their nucleotide sequences are
available upon request. PCR amplification was carried out
according to methods described previously (Horii et al., 1994)
with some modification. In brief, each 15 ,ul reaction mixture
containing 50 ng of DNA, 6.7 mM Tris-HCl (pH 8.8),
16.6 mm ammonium sulphate, 10 mM /3-mercaptoethanol,
6.7 !M EDTA, 6.7 mm magnesium chloride, 0.33 mM paired
labelled (with [y-32P]ATP) and unlabelled primer, 1.5 mM of
each deoxynucleotide and 0.75 units of Taq DNA polymerase
was prepared for PCR amplification of 40 cycles by the
following regimen: denaturation at 94°C for 30 s, annealing
at 53- 58°C for 30 s and extension at 72°C for 30 s. After
PCR amplification, each product was analysed by electro-
phoresis in 6% polyacrylamide/8 M urea/32% formamide
gels, followed by autoradiography.
Analysis of the results
For informative cases, results were analysed by quantitative
densitometry using NIH Image software. Allelic loss was
assigned if the intensity of one of the bands in the tumour
DNA was more than 50% reduced from that of correspond-
ing normal tissue. Statistical evaluations of possible
correlations between observed genotypes and clinical para-
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Table I Summary of 56 samples of endometrial cancer
Grade
1 22
2 19
3 13
Serous 1
Clear cell 1
FIGO stage
I 30
II 11
III 14
IV I
Age at surgery (years) 54.7+1.3
meters were performed with either the Fisher's exact test or
the x2 test with Yates correction.
Results
Initially, 42 microsatellite markers at one or more loci on all
non-acrocentric autosomal chromosome arms, as well as
chromosome X, were used to determine loci subject to allelic
deletions in 56 endometrial cancers by assessing LOH using
matched DNA pairs of normal and tumour tissues. The
histopathological grades, stages and age at surgery are
summarised in Table I, and the results of the LOH study
are summarised in Table II. Forty-three of the 56 cases (77%)
showed LOH of at least one locus. The mean fractional
allelic loss (FAL) was 0.11, a result consistent with the
previous study (0.094) by Peiffer et al. (1995). FAL value was
high in grade 3 cancers (0.16) and low in grade 2 cancers
(0.06). Allelic loss of more than 20% was detected on
chromosome arms Oq and 16q, as shown in Figure 1.
As 14 of 30 (47%) tumours showed LOH at DIOS587, we
focused on this region using an additional ten microsatellite
markers for further characterisation. Examples of autoradio-
graphs that indicate interstitial deletions are shown in Figure
2. In case 513, allelic loss at DIOS587 and retention at the
two flanking markers of DIOS187 and DIOS216 were
observed. Similarly, in case 515, allelic loss at DIOS587 and
retention at the two flanking markers of DIOS209 and
DlOS216 were observed. Results, as summarised in Figure 3,
indicated two commonly deleted regions, termed regions A
and B. Although region B was defined by two tumours, cases
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Figure 1 Frequency of allelic loss in individual chromosome
arms. Open and closed bars indicate short and long arms
respectively. Short arms of acrocentric chromosomes (chromo-
somes 13,14,15,21 and 22) were not determined.
513 and 515, we cannot totally exclude region B as a locus
containing a tumour-suppressor gene. According to reports
by Gyapay et al. (1994) and Chumakov et al. (1995), these
regions were estimated to be approximately 8 cM and 12 cM
respectively.
With regard to correlations of allelic loss at chromosome
arm lOq and clinical parameters including age, histological
grade, degree of progression and prognosis, losses of region
A were detected more frequently in endometrial cancers of
grade 1 than in those of grade 3 (P=0.005 by Fisher's exact
test), as summarised in Table III.
Replication errors (RERs) were observed at microsatellite
loci on all chromosome arms, and RERs at two or more
microsatellite loci were detected in 24 of 56 tumours (43%);
12 cases showed RERs at more than half of the microsatellite
markers. Examples of RER(+) cases are shown in Figure 4.
Case 55 gained a number of CA repeats at the D7S490 locus,
and case 75 lost a number of CA repeats at the D14S276
locus.
We further determined whether there was any correlation
between RER and allelic loss and/or clinicopathological
features and found an association between RER(+) and
histological grade, as summarised in Table IV. Although the
association was weak (P=0.03 by Fisher's exact test), RER
was detected more frequently in endometrial cancer of grade
Table II Frequency of LOH at 42 loci in 56 endometrial cancers
Chromsomal LOH/ Chromosomal LOHI
arm Locus informative (%) arm Locus informative (%)
lp D1S226 3/33 (9) 12p D12S336 2/25 (8)
lq DlS202 2/32 (6) 12q D12S353 4/26 (15)
2p 1D2S136 3/27 (11) 13q D13S165 3/32 (9)
2q D2S335 0/27 (0) 14q D14S276 3/30 (10)
3p D3S1067 2/32 (6) 15q D15S132 2/25 (8)
3q D3S1292 3/36 (8) 16p D16S403 5/33 (15)
4p D4S404 6/34 (18) 16q D16S514 8/40 (20)
4q D4S1565 2/36 (6) 17p TP53 4/36 (11)
Sp D5S419 3/32 (9) 17q D17S920 2/31 (6)
Sq D5S422 3/26 (12) 18p D18S452 3/32 (9)
6p D6S263 2/32 (6) D18S62 3/43 (7)
6q D6S268 1/31 (3) 18q D18S462 4/25 (16)
7p D7S484 2/31 (6) l9p D19S413 1/24 (4)
7q D7S490 4/31 (13) 19q D19S412 1/28 (4)
8p D8S560 1/34 (3) 20p D20S199 1/34 (3)
8q D8S273 4/32 (13) 20q D20S96 4/39 (10)
9p D9S270 1/20 (5) 21q D21S261 2/16 (13)
9q D9S261 4/33 (12) 22q D22S284 3/38 (8)
lop DlOSl91 5/33 (15) Xp DXS1055 3/26 (12)
lOq DIOS587 14/30 (47) Xq DXS1192 3/25 (12)
1lp D1I S899 4/37 (11)
llq DllS900 1/36 (3)LOH study of chromosome lOq in human endometrial cancer
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3 and clear cell adenocarcinoma than in other grades. No
other correlations including RER and LOH in lOq were
found. Since frequent mutations of a polyadenine (poly(A))
tract and two GT repeats within the coding region of the
transforming growth factor fl-receptor II (RII) gene were
reported in genetically unstable colorectal cancer cell lines
(Markowitz et al., 1995), we also analysed these regions in all
the tumours with the RER(+) phenotype. However, no
alteration was detected in any of the tumours (data not
shown).
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Figure 2 Examples of results of LOH study by microsatellite
markers in chromosome 10q. Cases 513 and 515 showed LOH at
D1OS587. Intensities of bands indicated by arrows in cases 513
and 515 were 51% and 78% reductions respectively. T and N
denote DNAs from tumour and normal tissues respectively.
Discussion
Allelotype studies in various types ofmalignant tumours were
performed to define areas of chromosomal loss in which
putative tumour-suppressor genes exist (Rodriguez et al.,
1994). According to previous reports, allelic losses of 30% or
more were reported in chromosome arms 3p, lOq, 17p and
18q in human endometrial cancers (Okamoto et al., 1991;
Jones et al., 1994; Fujino et al., 1994; Peiffer et al., 1995).
Although we did not find frequent LOH on 3p, 17p or 18q,
our data confirmed previous reports of frequent LOH in
lOq23-q26 (Jones et al., 1994; Peiffer et al., 1995). In the
present study, we were able to narrow this down and find two
commonly deleted regions of approximately 8 cM and 12 cM
in lOq25-q26.
Recently, MXII was mapped in lOq24-q25 (Wechsler et
al., 1994), which would act as a negative regulator of c-myc
(Zervos et al., 1993). Peiffer et al. (1995) suggested the
possibility of this gene as the tumour-suppressor gene for
endometrial cancer. However, MXII was reported to be
localised in two overlapping YAC clones at D1OS597 (Gray
et al., 1995). Hence, we conclude that MXII is outside of the
Table III Correlation of allelic loss at region A and histopatholo-
gical diagnosis
Gla G2 G3a Others
Loss 9 (45%) 7 (33%) 2 (15%) 0 (0%)
Retain 1 (5%) 8 (38%) 7 (54%) 1 (50%)
Not 10 (50%) 6 (29%) 4 (31%) 1 (50%)
informative
Total 20 21 13 2
aIncidence of allelic loss at region A was significantly high in Gl
tumours than in G3 ones (P=0.005 by Fisher's exact test).
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Figure 3 Detailed deletion map of chromosome 10q25-26 in endometrial cancer. Microsatellite markers and their locations are
illustrated on the left. Solid bars on the right indicate commonly deleted regions at 10q25-q26. Closed and open circles denote loss
and retention of heterozygosity respectively. Homozygous locus and microsatellite instability were marked by (-) and R
respectively.
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Figure 4 Examples of replication errors in paired tumour (T)
and normal (N) tissues at D7S490 and D14S276 loci. Arrows
indicate changes in the number of repeats.
two commonly deleted regions, although involvement of
mutations in MXI] cannot be totally excluded in human
endometrial carcinogenesis.
According to our results, allelic loss of region A was
associated with endometrial cancers of grade 1. This result
suggests a pathway of endometrial carcinogenesis. If
endometrial cancers develop sequentially from tumours of
grade 1 to grade 2 and then grade 3, genetic alterations
frequently detected in tumours of grade 1 should also be
frequently detected in tumours of grade 3. However, LOH of
region A was frequent only in cancers of grade 1, not in
grade 3. Thus, we speculate that there is a pathway(s) of
development of endometrial cancer of grade 3 distinct from
that originating from grade 1. Alternatively, there may be a
common genetic alteration(s) and additional genetic changes
would divide cancers of grade 1 from the others, and
mutations of the gene in region A would lead to cancers of
grade 1.
In the present study, we detected frequent microsatellite
instabilities (24 of 56, 43%), agreeing with previous reports
(Han et al., 1993; Risinger et al., 1993; Duggan et al., 1994;
Burks et al., 1994; Peiffer et al., 1995). In 12 cases that
showed RERs at more than half of the microsatellite loci,
one was a multiple primary cancer patient who had a somatic
mutation in hMLHJ in her endometrial cancer; no other
mutation in either hMLHI or hMSH2 was detected
Table IV Correlation of RER and clinicopathological features
RER(+) RER(-)
Grade
1 12 9
2 4 13
3 7 m *2
Clear cell 0
FIGO stage
I 14 11
II 5 6
III 5 7
Age (years) 55.0+ 1.8 53.7 +2.3
*Incidence ofRER( +) in G3 and clear cell was highly significant by
Fisher's exact test (P=0.03).
(Fukushige et al., 1996). These results suggest that mutations
of gene(s) other than hMLHI and hMSH2 are crucial in the
carcinogenesis of endometrial cancers of the RER(+)
phenotype. In terms of correlations of clinical features and
genetic instability, this RER(+) phenotype associated with
poorly differentiated tumours was the consistent result in a
previous report by Kobayashi et al. (1995). It is possible that
a gene(s), whose mutation causes grade 3 or clear cell
adenocarcinoma, may have a target sequence of genetic
instability within it. As we did not detect any mutations in
the RII gene, some gene(s) other than RII is/are responsible
for endometrial carcinogenesis. Further study is necessary to
understand the molecular mechanisms of endometrial
carcinogeneses.
Abbreviations
FAL, fractional allelic loss; LOH, loss of heterozygosity; PCR,
polymerase chain reaction; RER, replication error.
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